Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib
- PMID: 33112475
- PMCID: PMC7816240
- DOI: 10.1111/dth.14470
Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures



Similar articles
-
Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173.J Allergy Clin Immunol. 2017 Apr;139(4):1396-1399.e12. doi: 10.1016/j.jaci.2016.10.030. Epub 2016 Dec 29. J Allergy Clin Immunol. 2017. PMID: 28041677 No abstract available.
-
Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.Dermatol Online J. 2018 Jan 15;24(1):13030/qt3v77g2zg. Dermatol Online J. 2018. PMID: 29469766
-
Efficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy.BMJ Case Rep. 2017 Jul 24;2017:bcr2017219943. doi: 10.1136/bcr-2017-219943. BMJ Case Rep. 2017. PMID: 28739563 Free PMC article.
-
Livedoid vasculopathy - current aspects of diagnosis and treatment of cutaneous infarction.J Dtsch Dermatol Ges. 2013 May;11(5):407-10. doi: 10.1111/ddg.12064. Epub 2013 Feb 26. J Dtsch Dermatol Ges. 2013. PMID: 23437985 Review.
-
[Vasculitis and vasculopathy].Acta Med Croatica. 2012 Oct;66 Suppl 1:19-24. Acta Med Croatica. 2012. PMID: 23193816 Review. Croatian.
Cited by
-
Adalimumab in Treating Refractory Livedoid Vasculopathy.Vaccines (Basel). 2022 Apr 1;10(4):549. doi: 10.3390/vaccines10040549. Vaccines (Basel). 2022. PMID: 35455298 Free PMC article.
-
Refractory Segmental Hyaline Vasculitis Treated with Janus Kinase Inhibitor Tofacitinib: A Case Report.Clin Cosmet Investig Dermatol. 2025 Jun 12;18:1453-1457. doi: 10.2147/CCID.S530188. eCollection 2025. Clin Cosmet Investig Dermatol. 2025. PMID: 40529548 Free PMC article.
-
Livedoid vasculopathy: A review with focus on terminology and pathogenesis.Vasc Med. 2022 Dec;27(6):593-603. doi: 10.1177/1358863X221130380. Epub 2022 Oct 26. Vasc Med. 2022. PMID: 36285834 Free PMC article. Review.
-
Effective Treatment of Livedoid Vasculopathy With Oral Tofacitinib.Clin Case Rep. 2025 May 28;13(6):e70536. doi: 10.1002/ccr3.70536. eCollection 2025 Jun. Clin Case Rep. 2025. PMID: 40443500 Free PMC article.
-
Livedoid vasculopathy, calciphylaxis, and Martorell's hypertensive ulcer: update on ischemic ulcers due to impaired microcirculation of the lower limbs.An Bras Dermatol. 2025 Mar-Apr;100(2):215-227. doi: 10.1016/j.abd.2024.09.004. Epub 2025 Jan 22. An Bras Dermatol. 2025. PMID: 39848831 Free PMC article. Review.
References
-
- Kumar A, Sharma A, Agarwal A. Livedoid vasculopathy presenting with leg ulcers. Rheumatology (Oxford). 2019;58(11):2076. - PubMed
-
- Gardette E, Moguelet P, Bouaziz JD, et al. Livedoid vasculopathy: a French observational study including therapeutic options. Acta Derm Venereol. 2018;98(9):842‐847. - PubMed
-
- Kelly RI, Wee E, Tancharoen C, Tam MM, Balta S, Williams RA. Three cases of lymphocytic thrombophilic arteritis presenting with an annular eruption. Australas J Dermatol. 2018;59(2):e127‐e132. - PubMed
-
- Irani‐Hakime NA, Stephan F, Kreidy R, Jureidini I, Almawi WY. Livedoid vasculopathy associated with combined prothrombin G20210A and factor V (Leiden) heterozygosity and MTHFR C677T homozygosity. J Thromb Thrombolysis. 2008;26(1):31‐34. - PubMed
-
- Gao Y, Jin H. Efficacy of an anti‐TNF‐alpha agent in refractory livedoid vasculopathy: a retrospective analysis. Dermatol Treat. 2020;1‐6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical